Drug-loaded casein composite xerogel as well as preparation method and application thereof
By self-assembling ε-polylysine and sodium caseinate to form casein composite dry gel, the problems of high centrifugation cost and insufficient drug delivery stability of polyelectrolyte complexes in the prior art are solved, realizing efficient gastrointestinal sustained release and large-scale production of poorly soluble drugs, which is suitable for the prevention and treatment of ulcerative colitis.
Patent Information
- Application Number
- CN202411112955.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-14
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-14
AI Technical Summary
Existing bio-based polyelectrolyte complexes require ultra-high-speed centrifugation for pharmaceutical applications, which is costly and limits their large-scale promotion. Furthermore, the physicochemical stability of traditional oral drug delivery systems is insufficient, affecting drug delivery efficiency.
A casein composite dry gel was prepared by self-assembling ε-polylysine and sodium caseinate, and encapsulating hydrophobic drugs through hydrophobic interactions. This drug-loaded casein composite dry gel is suitable for encapsulation and gastrointestinal sustained release of poorly soluble small molecule compounds.
It improves the bioavailability of poorly soluble drugs, enables sustainable gastrointestinal release of drugs, reduces the frequency of administration, has good thermoplasticity and antibacterial properties, and is suitable for large-scale production and diversified oral drug delivery.
Smart Images

Figure CN118987240A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceutical excipients, and relates to a composite dry gel, in particular to a drug-loaded casein composite dry gel, and also to a preparation method and application of the composite dry gel. Background Art
[0002] Ulcerative colitis is characterized by chronicity, recurrence and high morbidity, and has become a major health problem worldwide. Ulcerative colitis mainly affects the colon and rectum, and its pathological characteristics include persistent inflammation, mucosal swelling and intestinal ulcers. Existing biologics, steroids or immunosuppressants can temporarily relieve symptoms, but the relief effect is poor and short-lived in most patients, accompanied by serious side effects such as nausea, headache and hypertension.
[0003] Oral medication is the main method for treating ulcerative colitis, however, the digestive process of the gastrointestinal tract will affect the delivery efficiency and effective delivery of oral drugs. Traditional oral drugs have low bioavailability and require frequent administration 1-2 times a day. pH-responsive drug delivery systems, such as hydrogels, liposomes, and polymer micelles, achieve targeted drug delivery by utilizing the digestive differences in different organ regions, which can delay drug diffusion to reduce the risk of drug degradation or clearance. However, the physicochemical stability of this type of oral drug delivery system is still insufficient, so the development of an oral delivery system with higher stability has certain practical significance.
[0004] Polyelectrolyte complexes with pH-responsive characteristics can effectively prevent the early release of drugs as oral delivery systems, and improve the stability and sustainability of oral administration. Polyelectrolyte complexes are usually complex condensed substances formed by two oppositely charged polyelectrolytes, and have been widely used in pharmaceutical science and biotechnology to control the encapsulation and release of drugs. Polyelectrolyte complexes can be designed in a "bottom-up" manner, and they have characteristics such as porous morphology, high fracture strain and self-healing, and their physical morphology can be regulated by adjusting the pH or ionic strength of the environment. At the same time, polyelectrolyte complexes prepared from natural biomacromolecules, such as proteins, peptides and polysaccharides, have broad application prospects in the fields of pharmaceutical raw materials and food ingredients, and can be used as oral drug delivery carriers. However, existing bio-based polyelectrolyte complexes usually require ultra-high-speed centrifugation (≥100,000 rpm), and the raw materials used are relatively expensive, which seriously limits the large-scale application and promotion of polyelectrolyte complexes. Summary of the invention
[0005] Purpose of the invention: The purpose of the present invention is to provide a drug-loaded casein composite dry gel, and also to provide a method for preparing the composite dry gel and its use in preparing drugs for preventing and treating ulcerative colitis.
[0006] Technical solution: The drug-loaded casein composite xerogel of the present invention is an irregular porous gel structure that encapsulates poorly soluble small molecule compounds; the casein composite xerogel is obtained by self-assembly of ε-polylysine and sodium caseinate, and then encapsulating hydrophobic drugs through hydrophobic interactions.
[0007] Wherein, the mass ratio of the sodium caseinate, ε-polylysine and the hydrophobic drug is 1:0.08-0.16:0.1-2.
[0008] Wherein, the hydrophobic drug is one or a combination of curcumin or isoliensinine.
[0009] The method for preparing the drug-loaded casein composite xerogel comprises the following steps:
[0010] (1) preparing an ε-polylysine solution and a sodium caseinate solution respectively, dispersing the hydrophobic drug in the sodium caseinate solution, then adding the ε-polylysine solution dropwise, and vortexing and shaking to fully mix to obtain a drug-loaded composite precipitate;
[0011] (2) taking the drug-loaded composite precipitate obtained in step (1), high-speed centrifugation, hot air drying or freeze drying to obtain the drug-loaded casein composite xerogel.
[0012] Wherein, in step (1), the volume ratio of the ε-polylysine solution to the sodium caseinate solution is 1:12.5-6.25, preferably 1:12.5.
[0013] Wherein, in step (1), the ε-polylysine solution and the sodium caseinate solution are prepared by dissolving ε-polylysine and sodium caseinate in phosphate buffer respectively, and the solution concentration is 1-5 g / L, preferably 5 g / L;
[0014] Wherein, in step (1), the mass ratio of the hydrophobic drug to sodium caseinate is 0.1 to 2;
[0015] Wherein, in step (1), the vortex oscillation time is and the speed is 20-100 rpm.
[0016] Wherein, in step (2), the high-speed centrifugation is carried out at 6000-7000 rpm for 30-40 min; and the drying treatment is hot air drying at 60-70°C.
[0017] The preparation method of the casein composite xerogel comprises the following steps: adding ε-polylysine solution dropwise to sodium caseinate solution, shaking the solution sufficiently, centrifuging at high speed, discarding the supernatant, and drying the precipitate; the high-speed centrifugation condition is 6000 rpm for 30 min; and the drying treatment is hot air drying at 60°C.
[0018] The invention also discloses the application of the drug-loaded casein composite xerogel in preparing medicine for preventing and treating ulcerative colitis.
[0019] The drug is slowly released in the gastrointestinal tract through oral administration to prevent and treat ulcerative colitis.
[0020] Principle of the invention: The drug-loaded casein composite dry gel of the present invention uses polypeptides and proteins as raw materials, has high biocompatibility, and is prepared under certain solution ion strength conditions (<500mM NaCl). The formation mechanism of the composite dry gel is the electrostatic interaction and hydrophobic interaction between biological macromolecules, and has plasticizing properties and the characteristics of sustainable degradation in the gastrointestinal tract. Its microstructure is an irregular porous structure with a high specific surface area. It is suitable for the encapsulation of poorly soluble small molecule compounds through shaking and centrifugation, and can convert the crystal structure of poorly soluble small molecule compounds into an amorphous form, thereby significantly improving its bioavailability. In the mouse colitis model induced by sodium dextran sulfate, the drug-loaded casein composite dry gel can be continuously released in the gastrointestinal tract. Compared with direct administration, it can effectively reduce the frequency of medication to achieve the purpose of preventing and treating ulcerative colitis.
[0021] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: (1) The drug-loaded casein composite dry gel of the present invention encapsulates poorly soluble small molecule compounds through hydrophobic interactions, thereby enhancing the bioavailability of poorly soluble drugs; (2) The preparation method is simple and feasible, and is suitable for large-scale production; (3) It is applied to the prevention and treatment of ulcerative colitis, has a sustained-release effect, and overcomes the defect of frequent administration; (4) The casein composite dry gel has good thermoplasticity and antibacterial properties, and is suitable as a pharmaceutical excipient; (5) The casein composite dry gel can become a good platform for diversified oral drug delivery and has transformation value. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 is the preparation method of the casein composite xerogel in Example 1, wherein a is the turbidity change of the system when the sodium caseinate solution is titrated with ε-polylysine, b is the hydrodynamic diameter change of the system when the sodium caseinate solution is titrated with ε-polylysine, c is the ζ-potential of the system when the sodium caseinate solution is titrated with ε-polylysine, d is the change of protein content in the system when the sodium caseinate solution is titrated with ε-polylysine, e is a schematic diagram of the preparation of the casein composite xerogel, and f is the effect of sodium chloride concentration on the formation of composite precipitates and composite xerogels;
[0023] Figure 2The physicochemical properties of the casein composite xerogel in Example 2 are characterized, wherein a is the water contact angle of the casein composite xerogel, b is the thermoplastic transition characteristics of the casein composite xerogel, c is the characterization of the casein composite xerogel, sodium caseinate and ε-polylysine by differential scanning calorimetry, d is the characterization of the casein composite xerogel, sodium caseinate and ε-polylysine by Fourier transform infrared spectroscopy, e is the characterization of the inhibitory effect of the casein composite xerogel on Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus by the inhibition zone method, and f is the characterization of the degradation of the casein composite xerogel in simulated gastric fluid by mass change and gel electrophoresis;
[0024] Figure 3 is the self-assembly of casein molecules and ε-polylysine in Example 3, wherein a is a coarse-grained molecular dynamics simulation, b is the radial distribution function (RDF) of water molecules around the self-assembled structure, c is the solvent accessible surface area (SASA), d is the radius of gyration (Rg), and e is the free energy landscape analysis;
[0025] Figure 4 The physicochemical properties of the curcumin-loaded casein composite xerogel in Example 4 are characterized, wherein a is the characterization of the curcumin-loaded casein composite xerogel by differential scanning calorimetry, and b is the characterization of the curcumin-loaded casein composite xerogel by Fourier transform infrared spectroscopy;
[0026] Figure 5 The present invention shows the effect of the curcumin-loaded casein composite xerogel on the prevention and treatment of colitis symptoms in mice induced by sodium dextran sulfate in Example 5, wherein a is a colon morphology diagram of the colon of each group of mice in different administration methods, b is a statistical diagram of the colon length of each group of mice in different administration methods, and c is a statistical diagram of the weight of each group of mice in different administration methods;
[0027] Figure 6 The physicochemical properties of the isoliensinine-loaded casein composite xerogel in Example 6 are characterized, wherein a is characterized by differential scanning calorimetry, and b is characterized by Fourier transform infrared spectroscopy;
[0028] Figure 7The present invention is the prevention and treatment of colitis symptoms in mice induced by sodium dextran sulfate by the isoliensinine casein composite dry gel in Example 7, wherein a is the establishment of an ulcerative colitis mouse model induced by sodium dextran sulfate and the dosing regimen, b is the weight change of mice in each group with different dosing methods (n=6), c is the change of disease activity index score of mice in each group with different dosing methods (n=6), d is the colon morphology of mice in each group with different dosing methods (n=6), e is the colon length statistics of mice in each group with different dosing methods (n=6), and f is the H&E staining of colon tissue of mice in each group with different dosing methods;
[0029] Figure 8 This is a physical picture of the morphology of casein composite dry gel loaded with different concentrations of curcumin. DETAILED DESCRIPTION
[0030] The technical scheme of the present invention is further described below in conjunction with the examples. The test materials used in the examples can all be purchased through conventional channels.
[0031] Experimental Materials:
[0032] Reagents: ε-polylysine (25% (w / v)) was provided by JNC, Japan, with a weight-average molecular weight of 3989 Da and a polydispersity index of 1.01. Sodium caseinate (nitrogen content 13.5%–16.0%, sodium content <3%) was purchased from Sigma-Aldrich. Isoliensinine was provided by CSNpharm, USA. Dextran sulfate sodium (DSS) was purchased from Biode Pharmaceutical Co., Ltd. (Shanghai, China). Simulated gastric fluid (SGF) was purchased from Beijing Regen Biotechnology Co., Ltd.
[0033] Animals: Male C57BL / 6 mice (5 weeks old, weighing 21-23 g) were purchased from Qinglongshan Animal Farm in Nanjing. The animal license number is SYXK (Jiangsu) 2018-0049. Mice were placed in a clean-grade experimental animal room with free access to standard pellet feed and drinking water. All animal experiments strictly followed the guidelines specified in the Guide for the Care and Use of Laboratory Animals.
[0034] Example 1
[0035] The casein composite xerogel of the present invention comprises the following steps:
[0036] like Figure 1 As shown in Figures ad, by monitoring the changes in the turbidity, hydrodynamic diameter, zeta potential and protein content of the system in which ε-polylysine is added dropwise to the sodium caseinate solution, the change in the titration endpoint is determined to determine the optimal ratio for obtaining the composite precipitate. Figure 1e in the figure is a method for preparing a casein composite xerogel. Specifically, sodium caseinate powder is dissolved in 5 mM phosphate buffer (pH 7.0), a 5 g / L sodium caseinate solution is prepared, stirred at 60°C for 2 hours, and then allowed to stand overnight to ensure that the protein is completely hydrated. ε-polylysine is prepared with the above phosphate buffer to prepare a 5 g / L ε-polylysine solution. The ε-polylysine solution is added dropwise to the sodium caseinate solution, wherein the volume ratio of the ε-polylysine solution to the sodium caseinate solution is 1:12.5. The resulting solution is then vortexed to fully mix the solution to obtain a composite precipitate; the composite precipitate is centrifuged at a speed of 6000 r.pm in a high-speed centrifuge for 30 minutes to obtain a casein composite xerogel, and then hot air dried at 60°C for 12 hours to obtain a yellow translucent sodium caseinate gel. Figure 1 The f in FIG. 5 represents the effect of sodium chloride concentration on the formation of the composite precipitate, indicating that it can be formed in a solution with a sodium chloride concentration of no more than 500 mM.
[0037] Example 2
[0038] The physicochemical properties of the casein composite xerogel prepared in Example 1 were characterized as follows:
[0039] (1) Wettability and thermoplasticity of casein composite xerogel:
[0040] like Figure 2 As shown in a, the dynamic contact angle of the casein composite xerogel gradually decreased from 76.57±6.76° to 69.20±7.39° within 3 min, indicating the hydrophilicity of the casein composite xerogel. Figure 2 The b in Figure 2 shows that the casein composite xerogel after absorbing water exhibits a thermoplastic transition after heating (80°C). Figure 2 As shown in (c), differential scanning calorimetry shows that the casein composite xerogel has a higher denaturation temperature than sodium caseinate and ε-polylysine, indicating that the formation of the casein composite xerogel helps to enhance the thermal stability of sodium caseinate.
[0041] (2) Characterization of the secondary structure of casein composite xerogel:
[0042] like Figure 2As shown in d, the characteristic peaks were analyzed by Fourier transform infrared spectroscopy. Amide band I (1600-1700cm-1) mainly comes from the stretching vibration of CO and CN groups. As shown in Table 1, the secondary structure content of the amide I region is reflected, including α helix, β fold, antiparallel β fold and random coil. Compared with sodium caseinate, the casein composite dry gel showed structural rearrangement and a more ordered structure. Specifically, the α-helix content of the casein composite dry gel increased to 5.80%, while the β-fold and β-turn contents increased to 26.48% and 7.89%, respectively. In contrast, the antiparallel β fold content decreased from 45.64% to 33.59%, and the random coil content decreased to 20.28%.
[0043] (3) Antibacterial properties of casein composite xerogel:
[0044] like Figure 2 As shown in Figure e, the antibacterial activity of casein composite xerogel against Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa was evaluated by the inhibition zone experiment. The diameter of the inhibition zone of casein composite xerogel against Staphylococcus aureus was 4.04±0.34mm, which was significantly larger than the diameter of the inhibition zone against Escherichia coli (3.29±0.23mm) and Pseudomonas aeruginosa (1.63±0.39mm).
[0045] This indicates that casein composite xerogel has certain antibacterial properties, and its inhibitory effect on Gram-positive bacteria is greater than that on Gram-negative bacteria.
[0046] Table 1 Characterization of secondary structure of casein composite xerogel
[0047]
[0048]
[0049] (4) Digestion of casein composite xerogel in simulated gastric juice:
[0050] like Figure 2 As shown in Fig. f, the relative mass of sodium caseinate gradually decreased within 2 hours. The content decreased to 69.10±6.92% at 30 minutes and further decreased to 33.65±1.89% at the end of digestion. At the same time, gel electrophoresis experiments showed that peptides with a molecular weight of less than 10 kDa gradually increased over time, indicating that the casein composite xerogel may be decomposed by pepsin.
[0051] Example 3
[0052] Self-assembly mechanism of casein molecules and ε-polylysine:
[0053] like Figure 3As shown in a, the self-assembly mechanism of ε-polylysine and sodium caseinate is explained by coarse-grained molecular dynamics simulation. The results show that ε-polylysine and sodium caseinate self-assemble to form nanorod-like structures within 1 microsecond. Figure 3 Figure b shows the radial distribution function (RDF) of water molecules around the self-assembled structure, indicating that water molecules are excluded from the hydrophobic region, resulting in an increase in the disorder of the self-assembled structure. Figure 3 As shown in c, the solvent accessible surface area (SASA) increases from 1350nm 2 Reduced to 976nm 2 This indicates that the hydrophobic structure of sodium caseinate is exposed. Figure 3 As shown in d, the radius of gyration (Rg) indicates the formation of a rod-like structure. Figure 3 As shown in (e), free energy landscape analysis reveals that the self-assembly formation path is associated with the reduction of Rg and SASA, indicating that both are prone to form nanorod-like structures.
[0054] Example 4
[0055] The drug-loaded casein composite xerogel of the present invention encapsulates curcumin, and the specific preparation method comprises the following steps:
[0056] (1) ε-polylysine and sodium caseinate are dissolved in phosphate buffer respectively to prepare ε-polylysine solution and sodium caseinate solution, the solution concentration is 5 g / L, and the volume ratio is 1:12.5; curcumin hydrophobic drug is dispersed in the sodium caseinate solution, and then the ε-polylysine solution is added dropwise, and the drug-loaded composite precipitate is obtained after vortexing and fully mixing;
[0057] (2) The drug-loaded composite precipitate obtained in step (1) was centrifuged at 6000 rpm and dried with hot air at 60° C. for 30 min to obtain the drug-loaded casein composite xerogel.
[0058] Characterization of the physicochemical properties of curcumin-loaded casein composite xerogel:
[0059] like Figure 4 As shown in a, the thermal properties of curcumin and curcumin-loaded casein composite xerogel were tested by differential scanning calorimetry. Curcumin powder showed a clear endothermic peak at 185°C, marking the melting point of curcumin crystals. As the quality of curcumin in the curcumin-loaded casein composite xerogel decreased, the absorption peak of curcumin shifted to a lower temperature, indicating that curcumin was transformed into an amorphous structure. Figure 4As shown in b, the structural properties of curcumin and curcumin-loaded casein composite xerogel were studied by Fourier transform infrared spectroscopy. The peak of curcumin at 3506 cm-1 corresponds to the OH stretching vibration of the phenolic group. The characteristic peak at 1510 cm-1 is the C=O stretching vibration, CCC and CC=O in-plane bending vibration. 1628 cm-1 and 1603 cm-1 are the stretching vibrations of C=C and C=O, respectively. With the increase of curcumin mass, amide A at 3387 cm-1 of casein composite xerogel shows red shift and attenuation, which indicates the weakening of intermolecular hydrogen bonds. When the mass ratio of curcumin to casein composite xerogel is less than or equal to 0.2, amide I shifts from 1654 cm-1 to 1633 cm-1, and amide II shifts from 1534 cm-1 to 1505 cm-1. This change of amide A, I and II is related to the electrostatic and hydrophobic interactions between curcumin and casein composite xerogel. However, when the mass ratio of curcumin to casein composite xerogel was greater than or equal to 0.5, an obvious characteristic peak of curcumin appeared, indicating that the crystalline and amorphous structures of curcumin existed in the casein composite xerogel.
[0060] Example 5
[0061] Curcumin-loaded casein composite xerogel prevents and treats colitis symptoms in mice induced by dextran sulfate sodium:
[0062] Experimental method: After C57BL / 6 mice were adaptively fed for 1 week, they were first given preventive medication for 3 days, and then 2% sodium dextran sulfate solution was freely drunk for 7 days to establish a colitis mouse model. The mice were randomly divided into groups, the normal group did not quote 2% sodium dextran sulfate solution, and the model group did not receive medication. The medication groups were: 300 mg / kg curcumin group (CUR-1 (300 mg / kg)) administered daily, 300 mg / kg curcumin group (CUR-3 (300 mg / kg)) administered every three days, 150 mg / kg curcumin casein composite dry gel group (CUR@SAL-3 (150 mg / kg)) loaded every three days, 300 mg / kg curcumin casein composite dry gel group (CUR@SAL-3 (300 mg / kg)) loaded every three days, and 150 mg / kg curcumin casein composite dry gel group (CUR@SAL-3 (450 mg / kg)) loaded every three days.
[0063] like Figure 5 As shown in a, after the experimental period, the colons of mice in each group were taken for measurement after the mice were treated. Figure 5 Figure b shows that compared with the CUR-1 (300 mg / kg) group, the CUR-3 (300 mg / kg) and CUR@SAL-3 (300 mg / kg) groups were able to significantly increase colon length. Figure 5Figure c shows that as the mass of encapsulated curcumin increases, the changes in colon length and body weight of mice in the group administered curcumin-loaded casein complex dry gel every three days are mass-dependent, indicating that curcumin-loaded casein complex dry gel can improve the colitis symptoms of mice.
[0064] Example 6
[0065] The drug-loaded casein composite xerogel of the present invention encapsulates isoliensinine, and the specific preparation method is the same as that of Example 4;
[0066] Characterization of the physicochemical properties of casein composite xerogel loaded with isoliensinine:
[0067] like Figure 6 As shown in a in the figure, the thermal properties of isoliensinine and isoliensinine-loaded casein composite dry gel were tested by differential scanning calorimetry. Isoliensinine powder showed an obvious endothermic peak at 115°C, marking the melting point of isoliensinine crystals. Isoliensinine-loaded casein composite dry gel showed an obvious endothermic peak at 83°C, but no obvious endothermic peak appeared at 115°C, indicating that isoliensinine was transformed into an amorphous structure. Figure 6 As shown in b, the Fourier transform infrared spectrum shows that isoliensinine has a peak at 3376 cm -1 and 1614cm -1 The peaks correspond to NH stretching vibration and in-plane bending vibration, respectively. After isoliensinine was encapsulated in casein composite xerogel, the NH characteristic peak was significantly red-shifted, indicating that isoliensinine existed in amorphous form in casein composite xerogel.
[0068] Example 7
[0069] Isoliensinine-loaded casein composite xerogel prevents and treats colitis symptoms in mice induced by sodium dextran sulfate:
[0070] Experimental method: The colitis mouse modeling method was the same as that in Example 5. Figure 7 As shown in a in FIG, the administration groups are: a group of isoliensinine administered at 75 mg / kg per day (ISO-1), a group of isoliensinine administered at 75 mg / kg every three days (ISO-3), a group of casein dry gel administered at 75 mg / kg every three days (SAL-3), and a group of casein dry gel containing 75 mg / kg isoliensinine administered at 75 mg / kg every three days (ISO@SAL-3).
[0071] (1) Improvement of colitis symptoms in mice by casein composite xerogel loaded with isoliensinine:
[0072] like Figure 7As shown in Figures b and c, compared with the normal group, the mice in the control group and SAL-3 group showed significant weight loss, diarrhea and bleeding symptoms (P<0.01), and their disease activity index (DAI) scores were higher. The mice in the ISO-1, ISO-3 and ISO@SAL-3 groups showed slight weight loss and symptom relief, and the DAI scores were lower.
[0073] (2) Improvement of colon length in colitis mice by casein composite xerogel loaded with isoliensinine:
[0074] After the experimental period, the colons of mice in each group were taken for measurement. Figure 7 As shown in d and e, compared with the normal group, the colon length of the control group mice was significantly shortened (P<0.001), and the colon length of the SAL-3 group mice was also significantly shortened (P<0.01). ISO-3 can alleviate the shortening of the colon in mice to a certain extent (P<0.01). Compared with the control group, there was no difference in the effect on the colon length of the ISO-1 group and the ISO@SAL-3 group mice (P>0.05). The results showed that the encapsulation of casein composite xerogel can achieve the sustained release of isoliensinine and improve the symptoms of colitis mice.
[0075] (3) Improvement of colonic lesions in colitis mice by casein composite xerogel loaded with isoliensinine:
[0076] After the experimental period, the colons of mice in each group were taken for histopathological analysis. Figure 7 As shown in f, the colon tissue structure of the normal group mice was intact, and the mucosa, crypts, and cells were neatly arranged. The colon tissue of the control group mice showed significant damage from colitis, with abnormal crypt structure, damaged epithelial cells, and signs of inflammatory cell infiltration. At the same time, enhanced neutrophil infiltration was observed in the colon tissue of the ISO@SAL-3 group mice. Compared with the control group mice, there was no obvious change in the colon tissue of the ISO-1 group and the ISO@SAL-3 group mice, indicating that the ISO@SAL-3 group can improve the symptoms of colitis in mice and can continuously release isoliensinine to achieve the purpose of reducing the frequency of administration.
[0077] Example 8
[0078] Effects of different curcumin addition amounts on the morphology of casein composite xerogels:
[0079] Compared with Example 4, by changing the amount of curcumin added in step (1), the following Figure 8 The results shown, where:
[0080] Table 2 Effect of different concentrations of curcumin on the morphology of casein composite xerogel
[0081]
[0082] In summary, the drug-loaded casein composite dry gel of the present invention encapsulates poorly soluble small molecule compounds through hydrophobic interactions, enhances the bioavailability of poorly soluble drugs, and has good thermoplasticity and antibacterial properties. It is applied to the prevention and treatment of ulcerative colitis, has a sustained-release effect, and overcomes the defects of frequent drug administration. It can be used as a good platform for diversified oral drug delivery and has transformation value.
Claims
1. A drug-loaded casein composite xerogel, characterized in that: The composite xerogel is an irregular porous gel structure that encapsulates poorly soluble small molecule compounds; the casein composite xerogel is obtained by self-assembly of ε-polylysine and sodium caseinate, and encapsulates hydrophobic drugs through hydrophobic interactions between molecules.
2. The drug-loaded casein composite xerogel according to claim 1, characterized in that: The mass ratio of the sodium caseinate, ε-polylysine and the hydrophobic drug is 1:0.08-0.16:0.1-2.
3. The drug-loaded casein composite xerogel according to claim 1, characterized in that: The hydrophobic drug is one or a combination of curcumin or isoliensinine.
4. A method for preparing the drug-loaded casein composite xerogel according to claim 1, characterized in that: The following steps are involved: (1) preparing an ε-polylysine solution and a sodium caseinate solution respectively, dispersing the hydrophobic drug in the sodium caseinate solution, then adding the ε-polylysine solution dropwise, and vortexing and shaking to fully mix to obtain a drug-loaded composite precipitate; (2) taking the drug-loaded composite precipitate obtained in step (1), high-speed centrifugation, hot air drying or freeze drying to obtain the drug-loaded casein composite xerogel.
5. The method according to claim 4, characterized in that: In step (1), the volume ratio of the ε-polylysine solution to the sodium caseinate solution is 1:12.5-6.
25.
6. The method according to claim 4, characterized in that: In step (1), the ε-polylysine solution and the sodium caseinate solution are prepared by dissolving ε-polylysine and sodium caseinate in phosphate buffer respectively, and the solution concentration is 1-5 g / L.
7. The method according to claim 4, characterized in that: In step (1), the vortex oscillation time is and the speed is 20-100 rpm.
8. The method according to claim 4, characterized in that: In step (2), the high-speed centrifugation is carried out at 6000-7000 rpm for 30-40 min; and the hot air drying treatment is carried out at a temperature of 60-70°C.
9. Use of the drug-loaded casein composite xerogel according to claim 1 in the preparation of a drug for preventing and treating ulcerative colitis.
10. The use according to claim 9, characterized in that: The drug can achieve the purpose of preventing and treating ulcerative colitis by sustained release in the gastrointestinal tract through oral administration.
Citation Information
Patent Citations
Hydrophobic drug and nutrient loaded casein / anionic polysaccharide nanoparticles and preparation method thereof
CN111012760A
